LINC01781: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC01781

NCBI ID: G101927412

LINC01781

Other Name(s): long intergenic non-protein coding RNA 1781 | Long intergenic non-protein coding RNA 1781, transcript variant 1

LINC01781: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC01781 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various studies as a potential drug target and biomarker. It is a non-coding RNA molecule that is located between the 5' and 3' ends of chromosome 18, and it has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation.

Drug Target Potential

LINC01781 has been identified as a potential drug target due to its unique structure and its involvement in several cellular processes. One of the key factors that make LINC01781 an attractive drug target is its cytoplasmic localization, which suggests that it is involved in the regulation of cell adhesion and migration. Additionally, studies have shown that LINC01781 is involved in the regulation of the expression of several genes that are involved in cell growth, survival, and angiogenesis, which further supports its potential as a drug target.

Biomarker Potential

In addition to its potential as a drug target, LINC01781 has also been identified as a potential biomarker for several diseases, including cancer. Several studies have shown that LINC01781 is expressed in various tissues and cells, including cancer cells, and that it is involved in the regulation of cellular processes that are associated with cancer progression. Additionally, studies have shown that LINC01781 is expressed in the blood vessels of cancer patients, which suggests that it may be a useful biomarker for cancer diagnosis and treatment.

Expression and Regulation

LINC01781 is a non-coding RNA molecule that is expressed in a variety of tissues and cells. It has been shown to be expressed in the brain, heart, liver, and other organs, as well as in various cell types, including cancer cells. LINC01781 is regulated by several factors, including the microRNA (miRNA) system, which is a complex of small non-coding RNAs that play a role in post-transcriptional gene regulation.

miRNA regulation of LINC01781

Several studies have shown that LINC01781 is regulated by the miRNA system, which is a complex of small non-coding RNAs that play a role in post-transcriptional gene regulation. miRNA are short for micro-RNA, and they are characterized by their ability to bind to specific mRNAs and their ability to regulate their stability.

Studies have shown that LINC01781 is regulated by several miRNAs, including miR-18a, miR-30a, and miR-1062. These miRNAs have been shown to bind to specific regions of the LINC01781 RNA molecule and to regulate its stability.

LINC01781 as a drug target

The potential drug target for LINC01781 is its involvement in cell adhesion, migration, and transcriptional regulation. LINC01781 has been shown to play a role in the regulation of cell adhesion by interacting with the protein E-cadherin. This interaction between LINC01781 and E-cadherin suggests that LINC01781 may be a useful drug target for diseases associated with cell adhesion and migration, such as cancer.

In addition, LINC01781 has also been shown to play a role in the regulation of transcriptional

Protein Name: Long Intergenic Non-protein Coding RNA 1781

The "LINC01781 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01781 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets